https://www.selleckchem.com/products/AZ-960.html
High rates of virologic response were demonstrated at Week 48 by ITT-FDA snapshot (acute 10/13 [76.9%]; early 37/43 [86.0%]) and observed (acute 10/11 [90.9%]; early 37/38 [97.4%]) analyses. No patients discontinued or required regimen change due to baseline resistance or lack of efficacy, or developed protocol-defined virologic failure. Through Week 48, 7 (53.8%) acute and 22 (51.2%) early infection patients had a D/C/F/TAF-related adverse event (AE); none had a D/C/F/TAF-related grade 4 or serious AE. High rates of viral suppression du
Like
Comment
Share
